Scadenza: 14 October 2021
Topic:
The aim of the action is to identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’ including by upscaling available innovation using advanced computing and the new big-data technologies and high-performance computing while reducing timeframes and development costs.
The action will launch an EU platform based on 'drug computational networks' to predict, in-silico, the efficacy of approved drugs against relevant tumor targets, as well as to select better responding patients or disease biomarkers. This will be implemented following a cost-effective and time-consuming approach, also building on drug re-use experiences for the treatment of COVID-19, where high computation will be used to rapidly test existing molecules and new drug combinations.
The action will also elaborate and test models for closer collaboration between the intended parties
Programma:
EU4 Health Programme (EU4H)
Ente finanziatore:
EU
Budget complessivo:
Available budget for this topic: EUR 3 000 000
Duration of the project: Proposals should range between 12 and 36 months,he recommended length of a project is 24-36 months.
Who can participate:
Applications by either a sole applicants or by a consortium are acceptable, but sole applicants or lead partners of a consortium need to provide proof of having prior relevant experience in the field concerned
Partnership: Not Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
The aim of the action is to identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’ including by upscaling available innovation using advanced computing and the new big-data technologies and high-performance computing while reducing timeframes and development costs.
The action will launch an EU platform based on 'drug computational networks' to predict, in-silico, the efficacy of approved drugs against relevant tumor targets, as well as to select better responding patients or disease biomarkers. This will be implemented following a cost-effective and time-consuming approach, also building on drug re-use experiences for the treatment of COVID-19, where high computation will be used to rapidly test existing molecules and new drug combinations.
The action will also elaborate and test models for closer collaboration between the intended parties
Who can participate:
Applications by either a sole applicants or by a consortium are acceptable, but sole applicants or lead partners of a consortium need to provide proof of having prior relevant experience in the field concerned
Programme:
EU4 Health Programme (EU4H)
Consortium: Not required
Status: Open
Total budget:
Available budget for this topic: EUR 3 000 000
Funding rate:
100%
Notes:
Applications by either a sole applicants or by a consortium are acceptable, but sole applicants or lead partners of a consortium need to provide proof of having prior relevant experience in the field concerned.
Proposals to be awarded under this topic: One single proposal, or up to 2.
